PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma - Wikidata - awgldk - TriplyDB

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

http://www.wikidata.org/entity/Q26766293

about

The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas Fibulin-4 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition via the PI3K/Akt/mTOR pathway.Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells microRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma Cells GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings Gab3 overexpression in human glioma mediates Akt activation and tumor cell proliferation.Overexpression of TELO2 decreases survival in human high-grade gliomas.Intravenous Formulation of HET0016 Decreased Human Glioblastoma Growth and Implicated Survival Benefit in Rat Xenograft Models Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells.AKT/GSK3β Signaling in Glioblastoma.MicroRNA-137 inhibits growth of glioblastoma through EGFR suppression.Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.Magnetic Resonance Imaging and Spectroscopy in Cancer Theranostic Imaging.Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer CENPH Inhibits Rapamycin Sensitivity by Regulating GOLPH3-dependent mTOR Signaling Pathway in Colorectal Cancer.Crosstalk between glial and glioblastoma cells triggers the "go-or-grow" phenotype of tumor cells.Rapamycin promotes differentiation increasing βIII-tubulin, NeuN, and NeuroD while suppressing nestin expression in glioblastoma cells Kaempferol induces autophagic cell death of hepatocellular carcinoma cells via activating AMPK signaling.The β-glucan from Lentinus edodes suppresses cell proliferation and promotes apoptosis in estrogen receptor positive breast cancers.Targeting cyclophilin-D by compound 19 protects neuronal cells from oxygen glucose deprivation/re-oxygenation.ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.Autophagy inhibition sensitizes LY3023414-induced anti-glioma cell activity in vitro and in vivo.LEF1-AS1, a long-noncoding RNA, promotes malignancy in glioblastoma.The long non-coding RNA CRNDE acts as a ceRNA and promotes glioma malignancy by preventing miR-136-5p-mediated downregulation of Bcl-2 and Wnt2.5-Aminolevulinic Acid Guided Sampling of Glioblastoma Microenvironments Identifies Pro-Survival Signaling at Infiltrative Margins.Overexpression of CAPN2 promotes cell metastasis and proliferation via AKT/mTOR signaling in renal cell carcinoma.mTOR-Dependent Cell Proliferation in the Brain.L-Carnitine Attenuates Cardiac Dysfunction by Ischemic Insults Through Akt Signaling Pathway.The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma.The effects of PI3K-mediated signalling on glioblastoma cell behaviour.Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway.Swelling-induced chloride current in glioblastoma proliferation, migration, and invasion.Activation of the mTOR signaling pathway in peritumoral tissues can cause glioma-associated seizures.EYA2 promotes lung cancer cell proliferation by downregulating the expression of PTEN.Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.Metformin inhibits TGF-β1-induced epithelial-to-mesenchymal transition-like process and stem-like properties in GBM via AKT/mTOR/ZEB1 pathway.NF-κB Signalling in Glioblastoma.

P2860

Q28554467-F32CBF14-223C-42C7-9076-9357930A2361 Q33591900-92DCA90D-8FD6-4D12-B419-0F3FD229C80C Q33598331-66F6CCEA-2024-4C76-8604-93BDF2F6CC1D Q33744196-FB236D36-0832-4CB0-8FF0-A3C3083ADBE8 Q33798642-DCC5F216-7B37-42CF-BFDF-1383554D510F Q36050424-890EAED1-36B2-49BC-94F3-BA4CB2C230BC Q36105554-284E3F96-B47D-48C7-B32A-305D00A30A32 Q36307539-38E8CCF9-4905-48AD-8351-04C822ECCA0C Q37564650-7063559C-DF52-4EEA-B9A4-11AEEE033EC2 Q37615383-2E5B6087-612F-4615-A17B-A1907FA59197 Q37709171-C3CE2752-650B-4D0E-A0F9-A7974D658D91 Q37710163-654B7B11-E330-4593-90B3-6C889DDA7AE9 Q37733071-53EA6461-6A3B-4E7E-BBCF-AFC2B8793B70 Q38743138-0368F7FC-2096-4A41-96F1-087A737A928C Q38982546-A1B3B1A5-B34D-431F-847B-F3670A82F29E Q39337955-558A1A22-723F-4E6F-B97F-736618DD4182 Q41440959-AB3C4932-55B2-4092-819C-71F4F63318E5 Q42010694-9F3CF9DD-1894-48D9-834F-927BEF77DCCA Q42244908-6C2FAD47-EBE3-4A3B-AB13-8A21C504F63E Q45175810-3D34AC28-6160-4944-9EE1-6618BEE4F7CA Q45770844-2ACAFB1E-B9BA-4C2A-8649-0EA1CE38E43B Q45823361-0ECF6BA1-5151-4E63-9402-0F35971011A2 Q47103348-96C097F4-1FAF-40D2-8082-34B0ED266122 Q47106122-7B425DAE-92E3-4321-862B-58E9477DFE0C Q47114133-E610D99A-3E49-4C84-91B2-09DEA7BD6104 Q47116860-2EDD1B10-E743-46CB-9F3C-C68F9B79DA29 Q47134867-CACE7F50-FFA1-497F-87E7-0B16D21B4A25 Q47143235-66ADC164-1A23-4C88-AD92-590A5E082FB3 Q47231432-CA7D8B9A-0600-4B5A-89A3-76FB0E31AD43 Q47705867-255E32B8-BA6A-4B96-908B-ADC9E0A06B57 Q47868509-57864FFC-C344-44D0-AF69-4C610275C43E Q47945880-6D50E85E-26BD-4024-A372-8720EE2C7757 Q48009516-EDE1CBC3-7FFC-4AF2-BD1B-FE2EF8AECEBF Q48089299-0B1D783F-2661-44F6-8458-1D6C4ED478AE Q48161755-CD4DF53D-23D3-450B-819B-F0A717F420E1 Q48504763-633F5280-BFE2-41AB-964B-502E80929641 Q49497954-0B85D474-6B9D-4001-A8F6-227624F41550 Q49952154-D130449A-BB1E-4D14-A2C7-A88AD855E0E6 Q50327413-337B3842-B392-4EC4-94A4-A397A91C8BAC Q52091959-6C9BEEC8-6F58-427F-B7E9-B4FB91FA6864

P2860

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

http://www.wikidata.org/entity/Q26766293

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

@ast

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

@en

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

@nl

type

label

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

@ast

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

@en

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

@nl

prefLabel

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

@ast

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

@en

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

@nl

P1433

Q26766293-0526EF6D-85C5-48C2-829C-F8C40D2DE214

P1476

Q26766293-180D622C-96F3-494A-9FFF-820288EBA976

P2093

Q26766293-0FC5F60C-206B-4F6F-B5BB-76BA47208C8F

Q26766293-1420B4D7-347F-4B79-A07F-578EE28E49E6

Q26766293-2FA89D5A-313C-48CB-A943-2612744FBA8D

Q26766293-81EC1258-A0F1-4A96-9C7C-ECBE9694427F

Q26766293-98A26105-6FF2-4FB4-8200-C14B41744027

Q26766293-A2021E43-DA3C-40DD-AC33-D9D01AE99678

Q26766293-FCC08707-CB4F-4F87-B781-88C891E2B40E

Q26766293-FE7C225A-A372-4191-A3D8-8563CE9286D1

P275

Q26766293-B08745EC-BAD5-41ED-98A1-B37E0AF9A2AC

P2860

Q26766293-02498461-671D-4C02-B0BB-CFDBE9E885F3

Q26766293-05944C3A-7BDC-4E11-8A07-773844492EC1

Q26766293-062A26BD-61A8-4364-91DB-1C3F4937768E

Q26766293-085F99ED-AC2E-45A9-8747-83E496200B84

Q26766293-09284235-2321-44A6-81A4-D2EF24FB16D3

Q26766293-0A899AFA-22C5-4F51-866E-B472583201BF

Q26766293-0BCDB2CA-01E6-4EEF-AC75-3BF45711F636

Q26766293-0CAA8134-708D-4859-8657-E1C12CDDE3E6

Q26766293-11F2EF95-97B2-4FE9-B862-C387786779FB

Q26766293-1329D317-39D7-4145-B176-94BD2266020C

P31

Q26766293-15F09905-F3A4-4E52-99D0-0B005CFE3701

Q26766293-83B59B7C-F216-4963-B166-1B0A7A3AFE6A

P3181

Q26766293-C096AF19-B0CA-45C8-BCC4-ECA36F2B40E4

P356

Q26766293-5686C247-665E-4DFD-8A2C-EFACBB810578

P407

Q26766293-B10859A5-C9A8-4A4F-9526-C8D1B1511E33

P5008

Q26766293-C6EFA071-0ED2-4B23-B1E3-DDA778BB6704

P577

Q26766293-B5696275-E0D6-4169-A715-7C5E50BEDBD8

Q26766293-C91EF4E4-67DD-4ED5-9545-B19E1F67546D

P698

Q26766293-7F008961-109A-4212-A0F7-4B8570A22EF6

P921

Q26766293-06D6DA9A-5071-4ED8-8523-2E63A3FAB793

Q26766293-624F8389-CBA6-4DBF-A19F-A85185AA3249

Q26766293-644BB7DC-F48A-431D-AADD-AA35106334F2

Q26766293-837A1F85-D3D2-46BD-887C-FD62D9B28FA4

Q26766293-95F23B59-F127-4626-B235-ED469900C4F0

Q26766293-9AC4B716-FB54-4239-A09E-73FF216D3746

Q26766293-B8402F3F-11D1-467A-9F10-A82560331052

P932

Q26766293-1A183330-33AD-4D28-B3D4-8E4AFDBC3969

P3181

P356

ONCOTARGET.7961

P1433

P1476

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

@en

P2093

Allen Yen

http://www.w3.org/2001/XMLSchema#string

Changjing Wu

http://www.w3.org/2001/XMLSchema#string

Enhua Wang

http://www.w3.org/2001/XMLSchema#string

Huadi Gu

http://www.w3.org/2001/XMLSchema#string

Liang Wang

http://www.w3.org/2001/XMLSchema#string

Liu Cao

http://www.w3.org/2001/XMLSchema#string

Nianci Chen

http://www.w3.org/2001/XMLSchema#string

Xiaoman Li

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

The PI3K pathway as drug target in human cancer

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

An integrated genomic analysis of human glioblastoma multiforme

ErbB receptors: from oncogenes to targeted cancer therapies

A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

High frequency of mutations of the PIK3CA gene in human cancers

P31

scholarly article

P3181

840840

http://www.w3.org/2001/XMLSchema#string

P356

10.18632/ONCOTARGET.7961

http://www.w3.org/2001/XMLSchema#string

P407

P5008

P577

2016-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2016-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26967052

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

proto-oncogene proteins

neoplasm proteins

P932

5078108

http://www.w3.org/2001/XMLSchema#string